Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (1122)	1/20/2006 3:54:03 PM
From: Biomaven	Read Replies (1) \| Respond to of 1154

I didn't listen to the CC, but going on the language used it's hard to see the FDA budging anytime soon. They already have a large study showing the rash was pretty insignificant if you just used the drug for a short time, so it's hard to see what more the company can do. The trouble is there are rashes and there are rashes. The rashes produced in the studies have all been harmless, but at the back of the FDA's mind is that some drug rashes can be very serious or even fatal. Why the FDA didn't state their position before approving the ABS trials I have no idea, unless something in the trial results worried them. The company could of course request an AC meeting on this and I think they could have a chance of getting the FDA overruled. I shouldn't really be speaking without listening to the CC, but I just don't have time to do so. Peter